You are here: Home » 2023 » Archives for October 2023

L’hôpital spécialisé et centre de recherche King Faisal réalise une greffe de foie avec donneur vivant intégralement robotisée en première mondiale

RIYAD, Arabie saoudite, 30 oct. 2023 (GLOBE NEWSWIRE) — L'quipe de chirurgiens en charge du centre d'excellence en transplantation d'organes de l'hpital spcialis et centre de recherche King Faisal (ci–aprs KFSH&RC ) marque l'histoire de la chirurgie robotique d'une pierre blanche en russissant la premire greffe de foie avec donneur vivant entirement robotise du Royaume. Cette innovation confirme l'hpital dans sa position de leader mondial des interventions chirurgicales mini–invasives.

Les chirurgiens se sont appuys sur une technologie robotique de pointe pour pratiquer d'infimes incisions cibles, induisant une phase d'invasion moindre pour le couple donneur – receveur, et sans avoir recours l'hybridation. Mme si d'autres centres ralisent dj des greffes de foie mini–invasives au moyen d'approches mixtes, le KFSH&RC est le premier centre avoir russi une greffe de foie avec donneur vivant entirement robotise.

Cette intervention exceptionnelle constitue une onde de choc dans les annales de la transplantation, et traduit bien l'engagement du centre en faveur de pratiques d'avant–garde visant optimiser les rsultats en matire de sant, amliorer le vcu des patients, et doper l'efficacit oprationnelle de l'hpital. La technique de chirurgie robotique adopte dans le cadre de cette transplantation a galement conduit rduire les risques de complications et le temps de rcupration des patients, mais aussi le sjour l'hpital.

Le KFSH&RC est partenaire sant stratgique de la Global Health Exhibition qui se tient Riyad du 29 au 31 octobre, et y prsente un forum de ses dernires innovations. Les participants pourront dcouvrir comment l'expertise du centre d'excellence en transplantation d'organes de l'hpital dans les applications chirurgicales de technologies de pointe contribue dpasser les frontires du possible en matire de soins de sant.

Le KFSH&RC a battu des records de russite en allogreffe rnale, une technique chirurgicale qui facilite les transplantations simultanes entre deux donneurs issus de familles diffrentes. En 2022, l'hpital a franchi la barre des 91 transplantations rciproques, surpassant ainsi tous ses homologues internationaux.

Pionnier mdical saoudien, le centre d'excellence en transplantation d'organes du KFSH&RC dispose des installations les plus avances et les plus perfectionnes en matire de transplantations multi–organes de tout le Moyen–Orient. Les services de l'hpital se spcialisent dans la transplantation d'organes solides : rein, foie, poumon, pancras et intestin.

Le KFSH&RC est mondialement reconnu pour ses contributions exceptionnelles aux soins de sant spcialiss, ainsi que pour son engagement en faveur de l'innovation et son attachement la recherche et l'ducation mdicale avance. Par ailleurs, le KFSH&RC affiche la ferme volont de dvelopper des technologies mdicales et de relever la norme applicable aux soins de sant l'chelle mondiale. En collaborant avec de grandes institutions locales, rgionales et internationales, l'hpital s'engage dans les meilleures pratiques cliniques, de recherche et d'ducation.

Coordonnes :
kfshrc@mcsaatchi.com

Des photos accompagnant ce communiqu est disponible au :
https://www.globenewswire.com/NewsRoom/AttachmentNg/888a9b0a–3cd2–4186–ab5e–b44eb8f0d9cb
https://www.globenewswire.com/NewsRoom/AttachmentNg/250c97ba–0d78–4a24–83a5–73e063b3366b


GLOBENEWSWIRE (Distribution ID 8968625)

King Faisal Specialist Hospital & Research Centre erreicht medizinischen Meilenstein mit weltweit erster vollständig robotergestützten Lebendspender-Lebertransplantation

RIAD, Saudi–Arabien, Oct. 30, 2023 (GLOBE NEWSWIRE) — Mit einer historischen Leistung hat das Team des Organ Transplant Centre of Excellence (OTCoE) am King Faisal Specialist Hospital & Research Centre (KFSH&RC) die weltweit erste vollstndig robotergesttzte Lebendspender–Lebertransplantation im Knigreich Saudi–Arabien erfolgreich durchgefhrt "" ein Schritt, der die Position des KFSH&RC als weltweit fhrende Institution in der minimal–invasiven Transplantationschirurgie festigt.

Mithilfe des bahnbrechenden Ansatzes des KFSH&RC und unter Einsatz modernster Robotertechnologie konnten sowohl die Operation des Spenders als auch der Eingriff am Empfnger przise und minimalinvasiv durchgefhrt werden, sodass kein Hybridverfahren erforderlich war. Whrend andere Zentren minimalinvasive Lebertransplantationen mit gemischten Operationstechniken anbieten, ist das KFSH&RC bislang das einzige Zentrum, das eine vollstndig robotergesttzte Lebendspender–Lebertransplantation erfolgreich durchfhren konnte.

Diese Errungenschaft stellt einen bedeutenden Sprung nach vorne in der Transplantationsgeschichte dar und ist zugleich Beweis fr das Engagement des Zentrums fr fortschrittliche Verfahren, die die Ergebnisse der medizinischen Versorgung verbessern, die Patientenerfahrung aufwerten und die betriebliche Effizienz des Krankenhauses erhhen. Auch eine Verringerung des Komplikationsrisikos, der Genesungszeit und der Dauer von Krankenhausaufenthalten konnte dadurch erzielt werden.

Als strategischer Gesundheitspartner auf der Global Health Exhibition, die vom 29. bis 31. Oktober in Riad stattfindet, stellt das KFSH&RC seine neuesten Innovationen auf dem Forum vor. Teilnehmende erhalten einen Einblick in die Kompetenz des OTCoE bei der Anwendung von Spitzentechnologien zur Erweiterung der Mglichkeiten im Gesundheitswesen.

Das KFSH&RC stellte zuletzt Rekorde bei der erfolgreichen Durchfhrung wechselseitiger Nierentransplantationen auf "" einem medizinischen Ansatz, der Nierentransplantationen zwischen zwei Spendern aus verschiedenen Familien gleichzeitig ermglicht. Im Jahr 2022 erreichte das Programm mit 91 wechselseitigen Transplantationen einen bemerkenswerten Meilenstein und bertraf seine internationalen Mitstreiter.

Das OTCoE des KFSH&RC gilt als Pionier im Knigreich und ist eine der fortschrittlichsten und umfassendsten Einrichtungen fr Multiorgantransplantationen im Nahen Osten. Die Leistungen umfassen Nieren–, Leber–, Lungen–, Bauchspeicheldrsen– und Darmtransplantationen, die zusammenfassend auch als "Transplantation fester Organe" bezeichnet werden.

Fr seine auergewhnlichen Beitrge zur spezialisierten Gesundheitsversorgung, sein Engagement fr Innovationen und seinen Einsatz fr die medizinische Spitzenforschung und –ausbildung ist das KFSH&RC weltweit anerkannt. Es ist darber hinaus bestrebt, medizinische Technologien zu entwickeln und weltweite Standard der Gesundheitsversorgung zu verbessern, indem es mit tragenden lokalen, regionalen und internationalen Institutionen zusammenarbeitet. Ziel des Krankenhauses ist es, Forschungs– und Bildungsdienstleistungen von Weltrang zu erbringen.

Kontaktinformationen:
kfshrc@mcsaatchi.com

Fotos zu dieser Ankndigung sind verfgbar unter:
https://www.globenewswire.com/NewsRoom/AttachmentNg/888a9b0a–3cd2–4186–ab5e–b44eb8f0d9cb
https://www.globenewswire.com/NewsRoom/AttachmentNg/250c97ba–0d78–4a24–83a5–73e063b3366b


GLOBENEWSWIRE (Distribution ID 8968625)

L’hôpital spécialisé et centre de recherche King Faisal présente les avancées de ses recherches biomédicales spatiales à la Global Health Exhibition

RIYAD, Arabie saoudite, 30 oct. 2023 (GLOBE NEWSWIRE) — L'hpital spcialis et centre de recherche King Faisal (ci–aprs KFSH&RC ) s'affiche en pionnier et prsente la fois ses perspectives en matire de recherche biomdicale spatiale et son rle dans l'amlioration de la sant la Global Health Exhibition, laquelle l'hpital participe au titre de partenaire sant stratgique.

Durant l'exposition, le KFSH&RC revient sur le ct indit de ses quatre conduites de recherche en sciences cellulaires dans l'espace. Ces expriences englobent des tests de rponse des cellules immunitaires l'inflammation dans l'espace, le suivi de l'activit des milliers de gnes des cellules immunitaires exposes l'inflammation au fil du temps, et la surveillance des mutations de la dure de vie de l'acide ribonuclique (ARNm) entre l'espace et la Terre. De plus, le pavillon KFSH&RC propose une simulation de rponse inflammatoire au traitement mdicamenteux au moyen d'un modle de cellule immunitaire visant explorer ses applications potentielles en prvention et en traitement prcoce.

Ces recherches menes en collaboration avec l'autorit spatiale saoudienne s'inscrivent dans le cadre de la mission scientifique des astronautes saoudiens Rayyanah Barnawi et Ali Al–Qarni vers la Station spatiale internationale (ou SSI). Elles ont pour but de contribuer la recherche prospective et son champ d'application en mdecine spatiale pour renforcer la scurit des chercheurs de l'espace et exploiter ces connaissances au profit de la communaut mondiale des patients.

L'quipe de recherche dirige par le Dr Khaled Saad Abu Khubrah, responsable du dpartement de la biomdicine molculaire et de la recherche au KFSH&RC, le Dr Wijdan Al–Ahmadi du KFSH&RC, et le Dr Edward Hattie du centre des technologies spatiales amricain BioServe, situ dans l'tat du Colorado, a pilot les expriences scientifiques pendant quatre jours.

Le KFSH&RC poursuit activement ses recherches en sciences biomdicales spatiales dans le but d'atteindre une meilleure comprhension des effets de la dficience en gravit et des radiations cosmiques sur le corps humain. Ces recherches exploitent un environnement spatial unique, et ouvrent la voie des expriences mdicales qui ne sont pas ralisables sur Terre, et notamment l'tude de la croissance des cellules et des tissus dans des conditions de microgravit. Cette analyse pourrait conduire des dcouvertes rvolutionnaires dans le traitement des maladies, ainsi qu' de nouveaux champs d'application de la mdecine spatiale.

Le KFSH&RC est mondialement reconnu pour ses services de soins de sant spcialiss et son leadership en matire d'innovation. L'hpital est un centre de recherche et d'ducation mdicale avanc, qui s'efforce de dvelopper des technologies mdicales et de faire voluer les soins de sant l'chelle mondiale en partenariat avec de grandes institutions locales, rgionales et internationales dans les domaines cliniques, de recherche et d'ducation.

Coordonnes :
kfshrc@mcsaatchi.com

Les photos jointes au prsent communiqu sont disponibles aux adresses suivantes :

https://www.globenewswire.com/NewsRoom/AttachmentNg/78eba5fa–19d6–437c–ab42–c9a09636e91e

https://www.globenewswire.com/NewsRoom/AttachmentNg/c30c198b–dd13–4d48–8b8c–6667eda49b45


GLOBENEWSWIRE (Distribution ID 8968479)

King Faisal Specialist Hospital and Research Centre präsentiert biomedizinische Weltraumforschung auf der Global Health Exhibition

RIAD, Saudi–Arabien, Oct. 30, 2023 (GLOBE NEWSWIRE) — Das King Faisal Specialist Hospital and Research Centre (KFSH&RC) prsentiert seine bahnbrechenden Entwicklungen und Zukunftsaussichten in der biomedizinischen Weltraumforschung sowie deren Rolle bei der Verbesserung der menschlichen Gesundheit auf der diesjhrigen Global Health Exhibition, an der das KFSH&RC auch als strategischer Gesundheitspartner teilnimmt.

Auf der Ausstellung berichtet das KFSH&RC ber seine wegweisenden Erfahrungen bei der Durchfhrung von vier Forschungsexperimenten im Bereich der Zellwissenschaften im Weltraum. Diese Experimente umfassen die Untersuchung der Reaktion von Immunzellen auf Entzndungen im Weltraum, die berwachung der Aktivitt von Tausenden von Genen in Entzndungen ausgesetzten Immunzellen und die Verfolgung von Vernderungen in der Lebensdauer von Ribonukleinsure (mRNA) zwischen Weltraum und Erde. Darber hinaus wird im Pavillon mithilfe eines Immunzellmodells die Entzndungsreaktion auf medikamentse Behandlung simuliert, was dazu dienen soll, mgliche Anwendungen fr die Prvention und Frhbehandlung zu erforschen.

Ziel dieser Forschungsexperimente, die in Zusammenarbeit mit der saudischen Raumfahrtbehrde und im Rahmen der wissenschaftlichen Mission der saudischen Astronauten Rayyanah Barnawi und Ali Al–Qarni zur Internationalen Raumstation (ISS) durchgefhrt werden, ist es, einen Beitrag zur Erforschung und Anwendung der Weltraummedizin zu leisten, um die Sicherheit von Raumfahrenden zu erhhen und die gewonnenen Erkenntnisse zum Nutzen von Patienten weltweit einzusetzen.

Die wissenschaftlichen Experimente dauerten vier Tage und wurden von einem Forschungsteam unter der Leitung von Dr. Khaled Saad Abu Khubrah, Leiter der Abteilung fr molekulare Biomedizin und Forschung am KFSH&RC, zusammen mit Dr. Wijdan Al–Ahmadi vom KFSH&RC und Dr. Edward Hattie vom BioServe Space Technologies Center im US–Bundesstaat Colorado durchgefhrt.

Das KFSH&RC setzt sich aktiv fr weitere Forschungen im Bereich der biomedizinischen Weltraumforschung ein, um ein umfassenderes Verstndnis der Auswirkungen von Schwerkraftmangel und kosmischer Strahlung auf den menschlichen Krper zu erlangen. Die Forscher mchten die einzigartige Weltraumumgebung nutzen, die Mglichkeiten fr medizinische Experimente bietet, die auf der Erde nicht durchfhrbar sind. Dazu gehrt die Untersuchung des Wachstums von Zellen und Geweben unter Mikrogravitationsbedingungen, die mglicherweise zu bahnbrechenden Entdeckungen bei der Behandlung von Krankheiten fhren und neue Wege in der Weltraummedizin erffnen knnte.

Das KFSH&RC ist weltweit fr seine spezialisierten Gesundheitsdienstleistungen und seine Innovationsfhrerschaft bekannt. Als fortschrittliches Zentrum fr medizinische Forschung und Ausbildung zielt es darauf ab, medizinische Technologien voranzutreiben und den Standard der Gesundheitsversorgung weltweit durch Partnerschaften mit fhrenden lokalen, regionalen und internationalen Institutionen in den Bereichen Klinik, Forschung und Ausbildung zu verbessern.

Kontaktinformationen:
kfshrc@mcsaatchi.com

Fotos zu dieser Mitteilung sind verfgbar unter:

https://www.globenewswire.com/NewsRoom/AttachmentNg/78eba5fa–19d6–437c–ab42–c9a09636e91e

https://www.globenewswire.com/NewsRoom/AttachmentNg/c30c198b–dd13–4d48–8b8c–6667eda49b45


GLOBENEWSWIRE (Distribution ID 8968479)

King Faisal Specialist Hospital and Research Centre Apresenta Suas Inovações e Soluções de Saúde na Global Health Exhibition

RIADE, Arábia Saudita, Oct. 30, 2023 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) apresenta sua jornada pioneira e perspectiva na rea de pesquisa biomdica no espao e seu papel no aprimoramento da sade humana na Global Health Exhibition 2023 onde o KFSH&RC tambm participar como parceiro estratgico de cuidado da sade.

Na Exposio, o KFSH&RC fala sobre sua experincia inovadora na conduo de quatro experimentos de pesquisa em cincias celulares no espao. Esses experimentos incluem o teste da resposta das clulas imunes inflamao no espao, monitoramento da atividade de milhares de genes nas clulas imunes expostas inflamao ao longo do tempo e o rastreamento das mudanas na vida til do cido ribonucleico (mRNA) entre o espao e a Terra. Alm disso, o pavilho simula a resposta inflamatria ao tratamento com drogas usando um modelo de clulas imunes para explorar suas aplicaes potenciais para preveno e tratamento antecipado.

O objetivo dessas experincias de pesquisa, conduzidas em colaborao com a Autoridade Espacial Saudita, como parte da misso cientfica dos astronautas sauditas Rayyanah Barnawi e Ali Al–Qarni na Estao Espacial Internacional (ISS), contribuir para a pesquisa exploratria e suas aplicaes na medicina espacial para aumentar a segurana dos exploradores espaciais e utilizar o conhecimento adquirido para o benefcio da comunidade de pacientes em todo o mundo.

Os experimentos cientficos duraram quatro dias e foram supervisionados pela equipe de pesquisa liderada pelo Dr. Khaled Saad Abu Khubrah, Chefe do Departamento de Biomedicina Molecular e Pesquisa do KFSH&RC, juntamente com o Dr. Wijdan Al–Ahmadi da KFSH&RC e o Dr. Edward Hattie do BioServe Space Technologies Center no Colorado, EUA.

O KFSH&RC est ativamente buscando se aprofundar mais nas pesquisas de cincia biomdica espacial para obter uma compreenso mais abrangente dos efeitos da deficincia da gravidade e da radiao csmica no corpo humano. Eles visam alavancar o ambiente espacial nico, que oferece oportunidades para experimentos mdicos que no so viveis na Terra. Incluindo o estudo de como as clulas e os tecidos crescem em condies de microgravidade, potencialmente levando a descobertas inovadoras para tratamentos de doenas e abrindo novos caminhos na medicina espacial.

O KFSH&RC reconhecido mundialmente por seus servios de sade especializados e sua liderana na inovao. Ele se destaca como um centro avanado de pesquisa e educao mdica, visando o avano das tecnologias mdicas e a elevao do padro de assistncia mdica em escala em todo o mundo, por meio de parcerias com instituies locais, regionais e internacionais nas reas de clnica, pesquisa e educacional.

Informaes de Contato:
kfshrc@mcsaatchi.com

Fotos deste comunicado podem ser encontradas em

https://www.globenewswire.com/NewsRoom/AttachmentNg/78eba5fa–19d6–437c–ab42–c9a09636e91e

https://www.globenewswire.com/NewsRoom/AttachmentNg/c30c198b–dd13–4d48–8b8c–6667eda49b45


GLOBENEWSWIRE (Distribution ID 8968479)

Impulse Dynamics Receives Full-Body MRI-Conditional Approval for Optimizer Smart Mini System

MARLTON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today it has received whole–body MRI–conditional approval for the Optimizer Smart Mini system from the United States Food and Drug Administration (FDA). The Optimizer Smart Mini system delivers the company's proprietary CCM therapy. This conditional approval expands the product labeling to allow for full–body magnetic resonance (MRI) diagnostic imaging with 1.5 and 3.0 Tesla (T) scanners. The approval for use with full–body MRI covers new patients adopting CCM therapy as well as existing Optimizer Smart Mini users.

"We are pleased to receive approval for this important labeling change reflecting a necessary option for heart failure patients who likely receive multiple surgeries and benefit from the use of MRI imaging in the course of their treatment," said Jason Spees, CEO of Impulse Dynamics. "This furthers our commitment to supporting the heart failure patients who benefit from important and life–changing CCM therapy with the Optimizer Smart Mini system."

"Full body MRI capability is part of our promise to deliver an ongoing pace of innovation," said David Prutchi, Ph.D., Chief Technology Officer, Impulse Dynamics. "This advance will ensure that patients who can benefit from our CCM therapy are able to pursue the option without limiting important future diagnostic options."

The Optimizer Smart Mini delivers CCM therapy to the heart. CCM therapy delivers precisely timed electrical pulses to the heart that are intended to improve the heart's ability to contract, allowing more oxygen–rich blood to be pushed out through the body.1 CCM therapy is indicated to improve 6–minute hall walk, quality of life, and functional status of NYHA (New York Heart Association) Class III heart failure patients who remain symptomatic despite guideline–directed medical therapy, are not indicated for CRT (cardiac resynchronization therapy), and have a left ventricular ejection fraction ranging from 25 to 45 percent.

The Optimizer Smart Mini incorporates a rechargeable battery with 20–year battery life, offering HF diagnostic monitoring that provides important clinical insights to providers to assist in managing their patients with heart failure. This latest generation also offers internal technology with improved programming and a smaller size designed to make the implant procedure faster and easier for patients and physicians.

Reference

1 Kuschyk J, Falk P, Demming T, et al. Long"term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system. European Journal of Heart Failure. 2021;23(7):1160–1169. doi:10.1002/ejhf.2202

# # #

About Impulse Dynamics
Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real–world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward–Looking Statements
This press release contains forward–looking statements. All statements other than statements of historical facts contained in this press release are forward–looking statements. In some cases, you can identify forward–looking statements by terms such as ""may,'' ""will,'' ""should,'' ""expect,'' ""plan,'' ""anticipate,'' ""could,'' ""intend,'' ""target,'' ""project,'' ""contemplate,'' ""believe,'' ""estimate,'' ""predict,'' ""potential'' or ""continue'' or the negative of these terms or other similar expressions, although not all forward–looking statements contain these words. Forward–looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy. These forward–looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward–looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company's future research and development costs, capital requirements and the company's needs for additional financing; commercial success and market acceptance of CCM therapy; the company's ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company's ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company's business model and strategic plans for its products, technologies and business, including its implementation thereof; the company's ability to expand, manage and maintain its direct sales and marketing organization; the company's ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company's ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward–looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward–looking statements contained herein. These forward–looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.

ID–A358–US

Attachments


GLOBENEWSWIRE (Distribution ID 8968472)

King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — In a new step that offers cancer patients a glimmer of hope and a lifeline, the King Faisal Specialist Hospital and Research Centre (KFSH&RC) celebrated its success in treating the 100th patient with lymphoid leukemia using Chimeric Antigen Receptor T–cell (CAR T–cell) therapy. This aligns with KFSH&RC's vision to be the optimal choice for specialized healthcare.

CAR T–cell therapy is an innovative treatment that enhances the ability of T–cells to recognize and destroy cancer cells after genetic modification in the laboratory to improve their targeting ability. This approach overcomes the challenge of distinguishing between cancer and normal cells, offering a promising method for treating lymphoid leukemia.

KFSH&RC emphasized that this innovative technology provides hope for patients with resistant leukemia and lymphoid tumors, especially those not effectively treatable with traditional methods.

As a strategic healthcare partner, KFSH&RC is sharing information about CAR T–cell therapy, its positive impact on healthcare improvement, and various healthcare solutions and innovations during the Global Health Exhibition taking place in Riyadh from October 29th to 31st.

KFSH&RC Hospital explained that this advanced therapy consists of four stages: extracting blood from the patient to obtain specific cells, then genetically modifying them in the lab for 3–4 weeks.

Shortly before CAR T–cell therapy, the patient receives a low dose of chemotherapy to enhance its effectiveness and the body's ability to fight cancer. Afterward, CAR T–cells are infused into the patient's arm, which is closely monitored for four weeks to ensure the body's adaptation.

The application of this advanced treatment in the Kingdom represents a qualitative addition to specialized medical care, reducing the financial, social, and health burdens of sending such cases abroad, aligning with Saudi Vision 2030 and its healthcare objectives.

King Faisal Specialist Hospital and Research Centre is globally recognized for offering this advanced form of treatment, thanks to its comprehensive therapeutic program featuring highly skilled medical, nursing, pharmaceutical, laboratory, and social specialists supported by an integrated infrastructure.

KFSH&RC is a global leader in specialized healthcare, innovation, advanced research, and medical education. It aims to develop medical technologies and elevate the standard of healthcare worldwide through partnerships with leading local, regional, and international institutions in clinical, research, and educational fields.

Contact information:
kfshrc@mcsaatchi.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9693817f–f8f6–4535–b14c–41f6801f16f7


GLOBENEWSWIRE (Distribution ID 8968450)

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — For the past four decades, the Cyclotron and Radiopharmaceuticals Department at King Faisal Specialist Hospital and Research Centre (KFSH&RC) has been addressing the needs of local and regional medical centers for radiopharmaceuticals used in diagnosing and treating various specialized diseases.

Since its establishment, the department has produced over 25 types of radiopharmaceuticals with a production capacity exceeding 600,000 radiopharmaceutical preparations. The department continues to provide its products to over 50 specialized Saudi medical centers, aiming to achieve self–sufficiency in the field of radiopharmaceuticals in the Kingdom of Saudi Arabia.

During the Global Health Exhibition that commenced yesterday in the capital city of Riyadh, where KFSH&RC participates as a strategic health partner, the hospital highlights the department's pioneering role in nuclear medicine. This includes enhancing the capabilities of healthcare providers in both research and education, as well as ensuring the quality in the production and distribution of radiopharmaceuticals to hospitals across the Kingdom and beyond.

The Cyclotron and Radiopharmaceuticals Department aspires to become a diagnostic and molecular imaging center and the first facility for Technetium–99m (Tc–99m) generators in the Kingdom. It conducts research to develop high–quality radiopharmaceuticals for KFSH&RC and other hospitals throughout the Kingdom to meet all healthcare needs of patients. The department adheres to high–quality standards for automated quality control and assurance while striving to advance cyclotron technology, precise radiopharmaceutical manufacturing, and the development of radiopharmaceuticals used in positron emission tomography/computed tomography (PET/CT).

The department significantly emphasizes quality, with an integrated product quality control and management unit, manufacturing materials following Good Manufacturing Practices (GMP), the Saudi Food and Drug Authority (SFDA) standards, and ISO 9001 international quality management system standards. All operational processes are subjected to rigorous monitoring for the periodic evaluation of materials, ensuring their continuous suitability. This approach has led to a remarkable customer satisfaction rate exceeding 95%.

KFSH&RC is globally recognized for providing specialized healthcare and is a leader in innovation, advanced medical research, and medical education. The institution actively seeks to develop medical technologies and enhance the standard of healthcare worldwide, partnering with leading local, regional, and international organizations to deliver world–class services in clinical, research, and educational domains.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/ad78d2ea–0d15–45ae–a3bd–cd25f7bf7ab9

https://www.globenewswire.com/NewsRoom/AttachmentNg/1d1f90e9–3a44–43cf–8812–af6760e2d0b2


GLOBENEWSWIRE (Distribution ID 8968426)

Zoom AI Companion hits one million meeting summaries milestone

SAN JOSE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — Today Zoom Video Communications, Inc. (NASDAQ: ZM) announced that Zoom AI Companion, the company's generative AI assistant, has reached a milestone less than two months after its launch, with more than 125,000 accounts using AI Companion, generating more than one million meeting summaries. Zoom also announced new capabilities, additional language support, and further enhancements to existing capabilities for AI Companion.

"Providing the best value to our customers across our platform is core to our mission, which is why we made AI Companion available at no additional cost,1 and we continue to introduce new AI capabilities at Zoom speed, so more of our customers can get the most out of Zoom's AI innovations," said Smita Hashim, chief product officer at Zoom. "Our unique federated approach allows us to dynamically utilize different models, helping to reduce AI overhead costs and provide broad access to generative AI."

New Zoom AI Companion capabilities
Beginning today, AI Companion users will be able to use the in–meeting questions capability in new languages, as well as receive short meeting summary overviews at the beginning of full meeting summaries.

  • Users can now use AI Companion's in–meeting questions capability in seven new languages (preview).
  • Based on feedback from users, the meeting summaries capability now includes an overview at the top of the summary in emailed summaries, providing users with a shorter version of the meeting summary in addition to the full meeting summary. Meeting summary overviews will be available in summaries delivered via continuous meeting chat in November.

AI Companion capabilities available in November

Zoom will continue to improve AI Companion, with the following new capabilities planned to be available in November:

  • Both AI Companion meeting summary and in–meeting questions capabilities will support a total of 32 new languages, in preview.
  • AI Companion will provide users with meeting coach capabilities, beginning with speech analytics in Smart Recordings. Speech analytics will include the meeting host's talk–listen ratio, talk speed, and speech fillers so that hosts can glean valuable insights into how they engage with meeting participants during Zoom Meetings.
  • AI Companion will be available in Zoom Events, with chat compose capabilities for lobby chats and assistance with composing emails for registration, marketing, and ticketing communications.
  • Zoom will introduce an optional control for customers to specify that AI Companion capabilities for their organization only use the Zoom large language model.

What Zoom customers are saying about AI Companion

"AI Companion's meeting summaries and smart recordings are the first technological innovations in the last decade that bring us tangible time–saving, efficient benefits. People can prioritize specific meetings and collaborations while remaining confident they aren't missing out on competing activities." – Chris Blackstone, director, Digital Workplace and End User Computing, Convera

"Zoom's AI Companion meeting summary tool is helping us become better communicators. Guided by its impressively accurate output, our teams are more consistently adhering to best practices in meetings such as stating the objective upfront and clearly outlining and assigning action items. Plus, we were able to save money by offboarding a vendor and save time by not having to produce meeting notes ourselves." – Lucas Oliveira, COO, Bizzycar, Inc.

"Meeting summaries has saved our team a ton of time. We feel that everyone is in the loop without necessarily having to attend every meeting, which results in better collaboration." – Karl Morsgofian, CIO, Gainsight

"Zoom's AI Companion exemplifies our vision for enhanced collaboration and innovation. With automated, detailed meeting summaries, it streamlines information sharing and boosts productivity. This inclusion in our Zoom plan not only improves efficiency but also yields significant cost savings, reflecting our commitment to a smarter, more connected future." – John Georgatos, CIO, Mike Morse Law Firm

AI Companion is available for eligible paid Zoom user accounts at no additional cost.1 For more information about Zoom AI Companion, visit the Zoom website.

About Zoom
Zoom is an all–in–one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Forward–Looking Statements

This press release contains express and implied "forward–looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits and potential of Zoom's generative AI assistant. In some cases, you can identify forward–looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," "target," "explore," "continue," or the negative of these terms, and similar expressions intended to identify forward–looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including those described under the caption "Risk Factors" and elsewhere in our most recent filings with the Securities and Exchange Commission, including our quarterly report on Form 10–Q for the fiscal quarter ended July 31, 2023. Forward–looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward–looking statements to reflect events or circumstances after the date they were made, except as required by law.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

1 Note: Included at no additional cost with the paid services assigned to Zoom accounts. AI Companion may not be available for all regions and industry verticals.


GLOBENEWSWIRE (Distribution ID 8968304)

Leading Japanese Telecommunications Carrier SoftBank Corp. Deploys Synchronoss Personal Cloud

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. ("Synchronoss" or the "Company") (Nasdaq: SNCR), a global leader and innovator in cloud, messaging, and digital products and platforms, today announced that SoftBank Corp. ("SoftBank"), one of Japan's largest telecommunication carriers, has deployed Synchronoss Personal Cloud to power its Anshin Data Box service.

Anshin Data Box allows customers to backup and restore photos, videos, and files stored on mobile phones and other devices. Additionally, the platform's artificial intelligence features provide the capability to optimize low resolution photos and create new types of content through a series of effects and stylizers.

Available in November across multiple distribution channels, SoftBank's Anshin Data Box will include 500 gigabytes of storage per month. Additionally, the personal cloud service will be integrated into new devices, allowing customers to easily activate it during the onboarding process. SoftBank will also deliver Anshin Data Box through its retail stores and digital buy flow.

"We continue to empower telecom operators and mobile service providers with strategic tools to improve customer value," said Jeff Miller, President and CEO of Synchronoss. "This new Cloud launch with SoftBank further extends our long–standing relationship with them and our presence in Japan. It also reinforces our cloud–first strategy, which represents new growth opportunities for the Synchronoss Personal Cloud platform."

About Synchronoss
Synchronoss Technologies (Nasdaq: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company's collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs, and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services, and content they love. Learn more at www.synchronoss.com.

Media Relations Contact:
Domenick Cilea
Springboard
dcilea@springboardpr.com

Investor Relations Contact:
Matt Glover and Tom Colton
Gateway Group, Inc.
SNCR@gateway–grp.com


GLOBENEWSWIRE (Distribution ID 8968023)